Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 5/20 | 0.40 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL5560785 | 0.92 | CTRB1 (0.43) | CTRB1CTSLCTSSSIRT2SYK | |
| Tetrabuthylammonium SCHEMBL4918810 | 0.85 | CTSK (0.47) | CTSS | |
| SCHEMBL5562553 | 0.81 | CTRB1 (0.52) | CTRB1CTSLCTSSSYK | |
| SCHEMBL5559459 | 0.80 | CTRB1 (0.51) | CTRB1CTSLCTSSSYK | |
| SCHEMBL14451984 | 0.78 | CTRB1 (0.49) | CTRB1CTSLCTSSSYK | |
| SCHEMBL5559542 | 0.76 | CTRB1 (0.56) | CTRB1CTSLCTSSSYK | |
| Tetrabuthylammonium SCHEMBL4918807 | 0.76 | CTSK (0.48) | CTSS | |
| Tetrabuthylammonium SCHEMBL27670752 | 0.76 | ALDH1A1 (0.38) | SIRT2SIRT1SIRT3 | |
| SCHEMBL4920665 | 0.73 | CTRB1 (0.50) | CTRB1CTSLCTSSSYKMME | |
| SCHEMBL4920658 | 0.73 | CTRB1 (0.50) | CTRB1CTSLCTSSSYKMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| EP-1758861-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | CTRB1 99/4885CTSL 71/4885CTSS 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.